Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5335 in Platinum-resistant Epithelial Ovarian Cancer (TREVI-OC-01)
NCT07218809Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Countries
- 24
01
Overview
A Phase 3 trial of AZD5335 in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started Dec 2025; status: recruiting.
02
Drugs
AZD5335
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07218809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218809.